Zoledronic acid-induced severe lymphopenia

Area of Science:

• Pharmacology
• Oncology
• Immunology

Background:

• Zoledronic acid is a bisphosphonate commonly used for osteoporosis, hypercalcemia, Paget's disease, and certain cancers.
• An acute phase response, characterized by symptoms like fever and fatigue, occurs in approximately 42% of patients post-treatment.
• Known side effects include temporary anemia, thrombocytopenia, and mild lymphopenia.

Observation:

• This report details a patient who developed severe lymphopenia after receiving a 5 mg zoledronic acid infusion for osteoporosis.
• This represents a previously undocumented severity of lymphopenia associated with zoledronic acid therapy.

Findings:

• The case demonstrates that severe lymphopenia can occur following zoledronic acid administration.
• This adverse event may be part of the acute phase response, though typically milder forms are reported.

Implications:

• Clinicians should be aware of the potential for severe lymphopenia as a rare adverse effect of zoledronic acid.
• Monitoring lymphocyte counts may be warranted in patients receiving zoledronic acid, particularly those with pre-existing immune concerns.
• Further research is needed to understand the mechanism and incidence of severe lymphopenia post-zoledronic acid.